| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
66,180,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Milestone Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Co.'s product candidate etripamil is a short-acting calcium channel blocker that Co. designed as a rapid-onset nasal spray to be self-administered by patients. Co. is developing etripamil for the treatment of specific arrhythmias with a lead indication to treat paroxysmal supraventricular tachycardia, with subsequent indications to treat atrial fibrillation and rapid ventricular rate and other cardiovascular indications.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2025-08-24 |
2025-05-23 |
2024-11-22 |
2023-11-23 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Bharucha David |
Chief Medical Officer |
• – – |
2025-07-11 |
4 |
A |
$0.00 |
$0 |
D/D |
53,333 |
63,333 |
|
- |
|
| Muller Lorenz |
Chief Commercial Officer |
• – – |
2025-07-11 |
4 |
A |
$0.00 |
$0 |
D/D |
66,666 |
175,052 |
|
- |
|
| Oliveto Joseph |
President and CEO |
• • – |
2025-07-11 |
4 |
A |
$0.00 |
$0 |
D/D |
66,666 |
347,221 |
|
- |
|
| Hasija Amit |
CFO & EVP of Corp. Development |
• – – |
2025-07-11 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
50,000 |
|
- |
|
| Wills Robert James |
|
– • – |
2025-07-11 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
65,000 |
|
- |
|
| Liebert Debra K. |
|
– • – |
2025-07-11 |
4 |
A |
$0.00 |
$0 |
D/D |
16,666 |
16,793 |
|
- |
|
| Papa Joseph C |
|
– • – |
2025-07-11 |
4 |
A |
$0.00 |
$0 |
D/D |
100,000 |
100,000 |
|
- |
|
| Wong Roderick |
10% Owner |
– – • |
2023-03-22 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,059,000) |
3,256,102 |
|
- |
|
| Bharucha David |
Chief Medical Officer |
• – – |
2022-12-05 |
4 |
B |
$4.69 |
$32,830 |
D/D |
7,000 |
10,000 |
2.74 |
- |
|
| Bharucha David |
Chief Medical Officer |
• – – |
2022-12-01 |
4 |
B |
$4.86 |
$14,580 |
D/D |
3,000 |
3,000 |
2.74 |
- |
|
| Liebert Debra K. |
Director |
– • – |
2022-10-21 |
4 |
B |
$5.26 |
$21,040 |
I/I |
4,000 |
4,000 |
2.1 |
- |
|
| Pasternak Richard C |
Director |
– • – |
2022-10-20 |
4 |
B |
$5.20 |
$52,000 |
D/D |
10,000 |
10,000 |
2.39 |
- |
|
| Liebert Debra K. |
Director |
– • – |
2022-10-20 |
4 |
B |
$5.29 |
$52,900 |
I/I |
10,000 |
10,000 |
2.1 |
- |
|
| Tomsicek Michael John |
Director |
– • – |
2022-10-19 |
4 |
B |
$5.32 |
$79,800 |
D/D |
15,000 |
15,000 |
2.39 |
- |
|
| Wills Robert James |
Director |
– • – |
2022-10-19 |
4 |
B |
$4.93 |
$73,950 |
D/D |
15,000 |
15,000 |
2.39 |
- |
|
| Liebert Debra K. |
Director |
– • – |
2022-09-14 |
4 |
A |
$0.00 |
$0 |
D/D |
127 |
127 |
|
- |
|
| Wong Roderick |
10% Owner |
– – • |
2022-09-07 |
4 |
S |
$8.71 |
$13,564,484 |
I/I |
(1,557,346) |
4,315,102 |
|
- |
|
| Wong Roderick |
10% Owner |
– – • |
2022-09-07 |
4 |
B |
$8.71 |
$13,564,484 |
I/I |
1,557,346 |
4,315,102 |
1.5 |
- |
|
| Truex Paul F |
Director |
– • – |
2022-05-31 |
4 |
B |
$5.60 |
$28,000 |
D/D |
5,000 |
81,780 |
2.39 |
- |
|
| Truex Paul F |
Director |
– • – |
2022-05-31 |
4 |
OE |
$1.12 |
$115,795 |
D/D |
76,780 |
76,780 |
|
- |
|
| Muller Lorenz |
Chief Commercial Officer |
• – – |
2020-08-26 |
4 |
OE |
$1.54 |
$8,778 |
D/D |
5,700 |
108,386 |
|
- |
|
| Fonds De Solidarite Des Travailleurs Du Quebec |
10% Owner |
– – • |
2020-07-29 |
4 |
S |
$8.32 |
$4,160,000 |
D/D |
(500,000) |
2,254,920 |
|
- |
|
| Fonds De Solidarite Des Travailleurs Du Quebec |
10% Owner |
– – • |
2020-07-28 |
4 |
S |
$8.10 |
$160,890 |
D/D |
(19,863) |
2,754,920 |
|
- |
|
| Muller Lorenz |
Chief Commercial Officer |
• – – |
2020-04-03 |
4 |
OE |
$1.54 |
$77,879 |
D/D |
50,571 |
102,686 |
|
- |
|
| Wong Roderick |
10% Owner |
– – • |
2020-03-19 |
4 |
B |
$10.87 |
$63,804 |
I/I |
5,870 |
4,315,102 |
1.5 |
- |
|
51 Records found
|
|
Page 1 of 3 |
|
|
